ANKE BIO: The "AK2017 Injection" is expected to initiate Phase III clinical trials in early next year

Zhitong
2025.10.29 07:28

ANKE BIO stated during an institutional research on October 28 that the clinical trial progress of its independently developed "AK2017 Injection" is going smoothly, having completed the enrollment for Phase II clinical trials. It has now submitted a supplementary application for Phase III clinical trials, which is expected to start in early next year

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer